GlassScriptPhysician profile
Norman J Riegel
NPI 1811069925
$8,170.35
in general payments reported to CMS, 2019-2025
40 companies · $1,285 in 2025
The $1,285 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,164 · 2020: $803 · 2021: $1,689 · 2022: $1,054 · 2023: $896 · 2024: $1,281 · 2025: $1,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,441 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,440.85 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,309.35 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $1,074.98 | 2020-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $612.41 | 2020-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $476.69 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $411.68 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.77 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $307.06 | 2019-2022 | |
| Amgen INC. | $300.75 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $296.64 | 2019-2025 | Watchman Flx, Watchman Access System |
| Medtronic, INC. | $280.42 | 2021-2024 | Selectsecure, Cobalt Dr Mri Surescan |
| Esperion Therapeutics, INC. | $261.72 | 2020-2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $252.94 | 2021-2025 | |
| Lilly USA, LLC | $236.91 | 2020-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $210.32 | 2019-2021 | |
| Abbott Laboratories | $208.87 | 2019-2025 | Cardiomems, Mitraclip |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $183.01 | 2023-2025 | Amvuttra |
| Heartflow, INC. | $150.76 | 2023-2025 | Ffrct |
| Glaxosmithkline, LLC. | $134.65 | 2021-2025 | Shingrix, Arexvy |
| Actelion Pharmaceuticals US, INC. | $126.37 | 2024 | Uptravi, Opsumit |
| Phathom Pharmaceuticals, INC. | $114.22 | 2024-2025 | Voquezna |
| Abbvie INC. | $113.32 | 2019-2025 | |
| Novo Nordisk INC | $104.71 | 2021-2024 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $95.75 | 2023-2025 | Cologuard Collection Kit |
| Cvrx, INC. | $80.33 | 2024 | Barostim Neo System |
| Edwards Lifesciences Corporation | $54.20 | 2021-2025 | Sapien 3 Ultra Resilia |
| Kowa Pharmaceuticals America, INC. | $48.83 | 2020-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $47.67 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $47.53 | 2019-2023 | |
| Daiichi Sankyo INC. | $43.25 | 2022-2023 | Injectafer |
| Bardy Diagnostics, INC. | $42.00 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.94 | 2019-2024 | Xifaxan, Trulance |
| Philips North America LLC | $31.31 | 2025 | Ecc Solutions |
| Atricure, INC. | $26.24 | 2021 | |
| Scpharmaceuticals INC. | $21.05 | 2024 | |
| Bridgebio Pharma, INC. | $20.86 | 2025 | Attruby |
| Azurity Pharmaceuticals, INC. | $19.37 | 2025 | Edarbi |
| Hikma Pharmaceuticals USA | $18.59 | 2020 | |
| Dexcom, INC. | $18.22 | 2022 | |
| Vivaquant INC, Dba Rhythm Express | $17.59 | 2025 | Rhythm Express |
| Astellas Pharma US INC | $17.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Riegel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.